Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics, Inc. is gaining traction in the pharmaceutical sector with its focus on developing innovative treatments for cancer, particularly through its lead candidate, rhenium (186Re) obisbemeda, which is under investigation for central nervous system cancers. The FDA's encouragement regarding an accelerated approval pathway for Reyobiq in treating leptomeningeal metastases highlights the significant unmet medical need in this area and suggests the potential for therapeutic success. Additionally, the company's recent public offering that raised approximately $15 million enhances its financial position, allowing for increased operational flexibility and advancement in pivotal trial preparations, thereby strengthening the outlook for Plus Therapeutics.

Bears say

The financial outlook for Plus Therapeutics Inc. is negatively impacted by a reduced price target, which has been lowered to $1.00 per diluted share from a previous target of $2.00, reflecting concerns about the company's valuation and potential market performance. Additionally, the uncertainty associated with the clinical study outcomes for its lead product, rhenium (186Re) obisbemeda, is heightened due to variability in median overall survival rates reported in prior studies, creating further challenges for investor confidence. Lastly, the recent equity offering and the anticipated exercise of associated warrants may dilute existing shareholder value, contributing to a cautious market sentiment towards the company.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.